RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5473.51M
Enterprise Value 3300.5M
Trailing P/E N/A
Forward P/E 1-2.62
PEG Ratio (5 yr expected) 1-0.25
Price/Sales (ttm)124.15
Price/Book (mrq)2.14
Enterprise Value/Revenue 378.79
Enterprise Value/EBITDA 6-2.12

Trading Information

Stock Price History

Beta (3Y Monthly) 0.72
52-Week Change 3-59.00%
S&P500 52-Week Change 30.90%
52 Week High 327.80
52 Week Low 310.37
50-Day Moving Average 312.06
200-Day Moving Average 313.51

Share Statistics

Avg Vol (3 month) 3424.16k
Avg Vol (10 day) 3373.08k
Shares Outstanding 536.78M
Float 36.82M
% Held by Insiders 11.25%
% Held by Institutions 185.34%
Shares Short (Jul 15, 2019) 45.21M
Short Ratio (Jul 15, 2019) 49.65
Short % of Float (Jul 15, 2019) 418.30%
Short % of Shares Outstanding (Jul 15, 2019) 411.85%
Shares Short (prior month Jun 14, 2019) 45.21M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-3,765.05%

Management Effectiveness

Return on Assets (ttm)-29.46%
Return on Equity (ttm)-62.41%

Income Statement

Revenue (ttm)3.81M
Revenue Per Share (ttm)0.10
Quarterly Revenue Growth (yoy)44.00%
Gross Profit (ttm)3.73M
EBITDA -141.64M
Net Income Avi to Common (ttm)-142.84M
Diluted EPS (ttm)-3.80
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)270.99M
Total Cash Per Share (mrq)6.16
Total Debt (mrq)31.53M
Total Debt/Equity (mrq)14.26
Current Ratio (mrq)8.13
Book Value Per Share (mrq)5.03

Cash Flow Statement

Operating Cash Flow (ttm)-104.52M
Levered Free Cash Flow (ttm)-71.09M